Fate Therapeutics files $350M ATM equity offering with Jefferies; terminates prior Leerink facility

FATE THERAPEUTICS INC

Filed universal shelf registration on Form S-3ASR for common stock, preferred stock, debt securities, warrants, and units.
Entered Open Market Sale Agreement with Jefferies to sell up to $350M of common stock in at-the-market offerings.
Jefferies will receive a 3% commission on gross proceeds; company not obligated to sell any shares.
Terminated prior at-the-market sales agreement dated November 21, 2018 with Leerink Partners effective upon filing.
Either party may suspend or terminate the offering upon notice subject to conditions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.